Akero Therapeutics, Inc. Proceeds from Issuance Initial Public Offering
Akero Therapeutics, Inc. reported Proceeds from Issuance Initial Public Offering of $105.80 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceInitialPublicOffering · last filed 2025-02-28
- Akero Therapeutics, Inc. proceeds from issuance initial public offering for the quarter ending 2024-12-31 was $0.00.
- Akero Therapeutics, Inc. proceeds from issuance initial public offering for the quarter ending 2024-09-30 was $0.00.
- Akero Therapeutics, Inc. proceeds from issuance initial public offering for the quarter ending 2024-06-30 was $0.00.
- Akero Therapeutics, Inc. proceeds from issuance initial public offering for the quarter ending 2024-03-31 was $105.80M.
- Akero Therapeutics, Inc. proceeds from issuance initial public offering for fiscal 2024 was $105.80M, a 0.00% change from fiscal 2023.
- Akero Therapeutics, Inc. proceeds from issuance initial public offering for fiscal 2023 was $105.80M, a 51.06% decline from fiscal 2022.
- Akero Therapeutics, Inc. proceeds from issuance initial public offering for fiscal 2022 was $216.20M.
- Akero Therapeutics, Inc. proceeds from issuance initial public offering for fiscal 2019 was $95.45M.
| Period end | Proceeds from Issuance Initial Public Offering 3 month | Proceeds from Issuance Initial Public Offering 6 month | Proceeds from Issuance Initial Public Offering 9 month | Proceeds from Issuance Initial Public Offering 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 derived: sum of 2 quarters · filed 2025-02-28 | $0.00 derived: sum of 3 quarters · filed 2025-02-28 | $105.80M 10-K · filed 2025-02-28 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $0.00 derived: sum of 2 quarters · filed 2024-11-08 | $105.80M 10-Q · filed 2024-11-08 | $105.80M derived: sum of 4 quarters · filed 2024-11-08 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $105.80M 10-Q · filed 2024-08-09 | $105.80M derived: sum of 3 quarters · filed 2024-08-09 | $105.80M derived: sum of 4 quarters · filed 2024-08-09 |
| 2024-03-31 | $105.80M 10-Q · filed 2024-05-10 | $105.80M derived: sum of 2 quarters · filed 2024-05-10 | $105.80M derived: sum of 3 quarters · filed 2024-05-10 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $105.80M 10-K · filed 2024-02-29 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $105.80M 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | $105.80M 10-Q · filed 2023-08-11 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $216.20M 10-K · filed 2023-03-17 | ||
| 2022-09-30 | $216.20M 10-Q · filed 2022-11-04 | |||
| 2020-09-30 | $202.55M 10-Q · filed 2021-11-12 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$1.63M derived: sum of 2 quarters · filed 2022-02-25 | $95.45M 10-K · filed 2022-02-25 | |
| 2019-09-30 | -$1.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $95.45M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $97.08M 10-Q · filed 2020-08-12 |